Galena Biopharma Inc
Change company Symbol lookup
Select an option...
GALE Galena Biopharma Inc
XCAPX ACAP Strategic Fund
CDXS Codexis Inc
CELG Celgene Corp
ATW Atwood Oceanics Inc
PM Philip Morris International Inc
MRK Merck & Co Inc
RAI Reynolds American Inc
HCN Welltower Inc
DUK Duke Energy Corp
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap GrowthCompany profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Price
Delayed
$0.42
Day's Change
-0.0063 (-1.48%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.43
Day's Low
0.4107
Volume
(Light)

Today's volume of 1,078,703 shares is on pace to be much lighter than GALE's 10-day average volume of 3,264,058 shares.

1,078,703
  • Prev Close
    0.4263
  • Today's Open
    0.42
  • Day's Range
    0.4107-0.43
  • Avg Vol (10-day)
    3.3M
  • Last (time)
    12:45p ET 08/30/16
  • Last (size)
    100
  • 52-Wk Range
    0.275 - 2.49
    LowHigh
  • (06/20/16 - 06/29/16)
    52.73%
  • 200.1%
  • Market Cap
    89.9M
  • Shares Outstanding
    214.0M
  • -0.13
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.9
  • 26.81
  • (% of float 08/15/16)
    8.31

Latest News

August 19, 2016
8:34 am ET
Zacks
August 10, 2016
8:32 am ET
MarketWatch
6:42 am ET
Zacks
August 09, 2016
4:07 pm ET
Globe Newswire
July 29, 2016
10:34 am ET
Zacks
July 26, 2016
9:12 am ET
Zacks
7:06 am ET
Globe Newswire
July 20, 2016
7:55 am ET
Zacks
7:40 am ET
PR Newswire
July 13, 2016
4:35 pm ET
Globe Newswire
July 08, 2016
7:35 am ET
Globe Newswire
7:05 am ET
Globe Newswire
July 01, 2016
11:54 am ET
PR Newswire
June 30, 2016
1:31 pm ET
PR Newswire
7:17 am ET
Zacks
June 29, 2016
7:05 am ET
Globe Newswire
June 23, 2016
8:10 am ET
Zacks
June 20, 2016
8:25 am ET
PR Newswire
June 13, 2016
7:05 am ET
Globe Newswire
June 10, 2016
2:46 pm ET
Globe Newswire
June 07, 2016
7:12 am ET
PR Newswire
June 06, 2016
2:00 pm ET
Globe Newswire
June 02, 2016
7:15 am ET
Zacks
June 01, 2016
7:05 am ET
Globe Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2016 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , and

Copyright © 2016. All rights reserved.